T-cell costimulation blocker

This page covers all T-cell costimulation blocker drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CD80/CD86 (via CTLA4-Ig fusion protein).

Targets

CD80/CD86 (via CTLA4-Ig fusion protein)

Phase 3 pipeline (2)

• Belatacept LI (less intensive) · Bristol-Myers Squibb · Immunology
  Belatacept is a selective T-cell costimulation blocker that inhibits T-cell activation by binding to CD80/CD86 on antigen-presenting cells.
• Belatacept MI (more intensive) · Bristol-Myers Squibb · Immunology
  Belatacept is a selective T-cell costimulation blocker that inhibits CD80/CD86 binding to CD28, preventing T-cell activation and proliferation.